Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 5
2003 16
2004 11
2005 8
2006 19
2007 13
2008 24
2009 15
2010 16
2011 13
2012 22
2013 29
2014 21
2015 13
2016 14
2017 16
2018 8
2019 4
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

244 results
Results by year
Filters applied: . Clear all
Page 1
Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D, Gordon C. Geh D, et al. Expert Rev Clin Immunol. 2018 Apr;14(4):245-258. doi: 10.1080/1744666X.2018.1450141. Epub 2018 Mar 20. Expert Rev Clin Immunol. 2018. PMID: 29542345 Review.
New treatments are needed for the management of active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets CD22 resulting in selective B cell modulation that has been considered a potential treatment for SLE. Areas covered: Summary of the relevant pathogen …
New treatments are needed for the management of active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets CD22 resu …
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group. Clowse ME, et al. Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856. Arthritis Rheumatol. 2017. PMID: 27598855 Free PMC article. Clinical Trial.
OBJECTIVE: Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. ...Patients were randomized 1:1:1 to receive either placebo, epratuzumab 600 mg every week, or epratuzumab 1,2 …
OBJECTIVE: Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the num …
Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R, Favretto D, Granzotto M, Decorti G, Rabusin M, Stocco G. Franca R, et al. Curr Med Chem. 2017;24(11):1050-1065. doi: 10.2174/0929867324666170113105733. Curr Med Chem. 2017. PMID: 28088906 Review.
CONCLUSION: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in comparison to conventional therapies are expected in the next years. Epratuzumab seems safe in the dosing scheme proposed in ALL, bu …
CONCLUSION: Phase 3 studies have recently begun and more consistent results about epratuzumab and blinatumomab safety and efficacy in …
Epratuzumab for systemic lupus erythematosus.
Wallace DJ, Goldenberg DM. Wallace DJ, et al. Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692. Lupus. 2013. PMID: 23553783 Review.
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). ...
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
Li J, Wei MM, Song Q, Guo XH, Shao L, Liu Y. Li J, et al. Exp Ther Med. 2019 Aug;18(2):1500-1506. doi: 10.3892/etm.2019.7630. Epub 2019 May 29. Exp Ther Med. 2019. PMID: 31316634 Free PMC article.
Systemic lupus erythematosus (SLE) is a remarkable and challenging autoimmune disorder that is characterized by a broad range of clinical manifestations, such as flares and remissions. Recently, the humanized anti-CD22 antibody epratuzumab for SLE has been extensively stud …
Systemic lupus erythematosus (SLE) is a remarkable and challenging autoimmune disorder that is characterized by a broad range of clinical ma …
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Wegener WA, Goldenberg DM, Meno-Tetang G, Kosutic G, Gordon C. Gottenberg JE, et al. Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12. Arthritis Rheumatol. 2018. PMID: 29381843 Free PMC article.
The aim of this post hoc analysis was to determine whether epratuzumab had a different clinical efficacy profile in SLE patients with versus those without an associated diagnosis of Sjogren's syndrome (SS). METHODS: The efficacy and safety of epratuzumab were compar …
The aim of this post hoc analysis was to determine whether epratuzumab had a different clinical efficacy profile in SLE patients with …
Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.
Al Rayes H, Touma Z. Al Rayes H, et al. Drug Des Devel Ther. 2014 Nov 17;8:2303-10. doi: 10.2147/DDDT.S49778. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25429203 Free PMC article. Review.
Epratuzumab is currently in a Phase III study evaluating its efficacy in the management of moderate to severe SLE. All published trials on epratuzumab have shown great promise with safe profiles....
Epratuzumab is currently in a Phase III study evaluating its efficacy in the management of moderate to severe SLE. All published tria
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T, Shock A, Goldenberg DM, Lipsky PE. Dörner T, et al. Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23. Autoimmun Rev. 2015. PMID: 26212727 Free article. Review.
Epratuzumab is a B-cell-directed non-depleting monoclonal antibody that targets CD22. ...Together, these data indicate that epratuzumab therapy affords a unique means to modulate BCR complex expression and signalling....
Epratuzumab is a B-cell-directed non-depleting monoclonal antibody that targets CD22. ...Together, these data indicate that epratu
Epratuzumab in the therapy of oncological and immunological diseases.
Goldenberg DM. Goldenberg DM. Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53. doi: 10.1586/14737140.6.10.1341. Expert Rev Anticancer Ther. 2006. PMID: 17069520 Review.
A second candidate target is CD22. The first antagonistic antibody to this B-cell marker, epratuzumab, appears to function, in contrast to CD20 antibodies, more by modulation of B cells rather than by their high depletion in circulation. Originally developed for the treatm …
A second candidate target is CD22. The first antagonistic antibody to this B-cell marker, epratuzumab, appears to function, in contra …
244 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page